Currently out of the existing stock ratings of Matthew Sykes, 57 are a HOLD (33.93%), 87 are a BUY (51.79%), 24 are a SELL (14.29%).

Matthew Sykes

Work Performance Price Targets & Ratings Chart

Analyst Matthew Sykes, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 57.67% that have a potential upside of 21.31% achieved within 95 days.

Matthew Sykes’s has documented 328 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on TXG, 10X Genomics at 30-Oct-2024.

Wall Street Analyst Matthew Sykes

Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.

Average potential price target upside

of $77.33 (15.84%) on TMO (THERMO FISHER SCIENTIFIC).
of $53.17 (3.98%) on MTD (METTLER-TOLEDO INTERNATIONAL).
of $23.91 (12.04%) on DHR (DANAHER).

DHR Danaher MRVI Maravai Lifesciences Holdings NAUT Nautilus Biotechnology NTRA Natera NVTA Invitae Corp PKI PerkinElmer TMO Thermo Fisher Scientific TXG 10X Genomics WAT Waters ZY Zymergen OMIC Singular Genomics Systems GH Guardant Health MYGN Myriad Genetics NEO NeoGenomics QTRX Quanterix Corp CTKB Cytek Biosciences HLTH Cue Health OLK Olink Holding AB ADR TX Ternium SA ADR CDNA Caredx MTD Mettler-Toledo International SMFR Sema4 Holdings Corp AVTR Avantor EXAS EXACT Sciences BRKR Bruker LMDX LumiraDx Ltd TWST Twist Bioscience Corp A Agilent Technologies DNA Ginkgo Bioworks Holdings QGEN Qiagen NV VCYT Veracyte PACB Pacific Biosciences of California

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Doug Schenkel (WOLFE)